Status:

COMPLETED

Hyperspectral Imaging to Assess and Predict Diabetic Foot Ulcers

Lead Sponsor:

HyperMed

Collaborating Sponsors:

The Cleveland Clinic

Olive View-UCLA Education & Research Institute

Conditions:

Diabetic Foot Ulcers

Eligibility:

All Genders

21-85 years

Brief Summary

This study is designed to test a prototype imaging instrument that relies on Medical HyperSpectral Imaging (MHSI) technology for the assessment and prediction of diabetic foot ulceration and wound hea...

Detailed Description

ULCER HEALING STUDY: This is a study comparing measurements from a cohort of 66 diabetic subjects (30 Type 1 and 36 Type 2) with at least one foot ulcer. The study will take place at three medical cen...

Eligibility Criteria

Inclusion

  • Ulcer Healing Study
  • Inclusion Criteria:
  • Subjects with Type 1 diabetes (defined as diabetes beginning before age 35, requiring insulin, and diagnosed with diabetes for more than six months) or Type 2 diabetes.
  • Presence of at least one foot ulcer
  • Exclusion criteria:
  • Peripheral arterial occlusive disease (PAD) that is severe enough to require surgical bypass operation.
  • Cardiovascular disease as demonstrated in only these instances: congestive heart failure that leads to severe edema at the lower extremity, stroke or transient ischemic attack with residual nerve dysfunction.
  • Uncontrolled hypertension: SBP\>190 mmHg or DBP \> 110 mmHg
  • End stage renal disease (subjects on renal dialysis or kidney transplantation)
  • Any other serious chronic disease that can affect wound healing
  • Subjects currently on any of the following medications: Glucocorticoids, Antineoplastics
  • Females if lactating or pregnant or, if of childbearing potential, unwilling to use standard birth control. All females of childbearing potential will undergo a pregnancy test during each visit.
  • NEW ULCER PREDICTION STUDY:
  • Inclusion criteria:
  • Subjects with Type 1 diabetes (defined as diabetes beginning before age 35, requiring insulin, and diagnosed with diabetes for more than six months) or Type 2 diabetes.
  • Subject without foot ulcers but at "high risk" for foot ulceration. In order to define "high risk" for this study, we are using the International Working Group standards:
  • Advanced neuropathy, defined by loss of protective sensation in the foot with a vibrational perception threshold (VPT) over 25mHz or inability to detect Semmes Weinstein 5.07 (10g) monofilament
  • Presence of significant deformity
  • Peripheral vascular disease with ankle brachial index \< 0.7
  • History of previous ulceration or presence of a foot ulcer
  • At least one foot that is ulcer free at the time of enrollment
  • Exclusion criteria:
  • Peripheral arterial occlusive disease (PAD) that is severe enough to require surgical bypass operation.
  • Cardiovascular disease as demonstrated in only these instances: congestive heart failure that leads to severe edema at the lower extremity, stroke or transient ischemic attack with residual nerve dysfunction.
  • Uncontrolled hypertension: SBP \> 190 mmHg or DBP \> 110 mmHg
  • End stage renal disease (subjects on renal dialysis or kidney transplantation)
  • Any other serious chronic disease that can affect wound healing
  • Subjects on any of the following medications: Glucocorticoids and Antineoplastic agents
  • Females if lactating or pregnant or, if of childbearing potential, unwilling to use standard birth control. All females of childbearing potential will undergo a pregnancy test during each visit.

Exclusion

    Key Trial Info

    Start Date :

    March 1 2006

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    September 1 2008

    Estimated Enrollment :

    256 Patients enrolled

    Trial Details

    Trial ID

    NCT00617916

    Start Date

    March 1 2006

    End Date

    September 1 2008

    Last Update

    June 4 2009

    Active Locations (3)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (3 locations)

    1

    Olive View UCLA Medical Center

    Sylmar, California, United States, 91342

    2

    Lerner Research Institute, The Cleveland Clinic

    Cleveland, Ohio, United States, 44195

    3

    University of Pennslyvania Healthcare System

    Philadelphia, Pennsylvania, United States, 19104

    Hyperspectral Imaging to Assess and Predict Diabetic Foot Ulcers | DecenTrialz